Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial

Di Lorenzo Giuseppe; Autorino Riccardo; Sonpavde Guru

首页> 外文期刊>European urology >Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial

【24h】

Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial

机译：回复：雄激素剥夺疗法加多西他赛和雌莫司汀与单独的雄激素剥夺疗法用于高危局限性前列腺癌（GETUG 12）：3期随机对照试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2015年第6期|共3页
作者
Di Lorenzo Giuseppe; Autorino Riccardo; Sonpavde Guru;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial [J] . Fizazi Karim, Faivre Laura, Lesaunier Francois, The lancet oncology . 2015,第7期

机译：雄激素剥夺疗法加多西他赛和雌莫司汀与单独的雄激素剥夺疗法治疗高危局限性前列腺癌（GETUG 12）：3期随机对照试验
2. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial [J] . Di Lorenzo Giuseppe, Autorino Riccardo, Sonpavde Guru European urology . 2015,第6期

机译：回复：雄激素剥夺疗法加多西他赛和雌莫司汀与单独的雄激素剥夺疗法用于高危局限性前列腺癌（GETUG 12）：3期随机对照试验
3. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial [J] . Di Lorenzo Giuseppe, Autorino Riccardo, Sonpavde Guru European urology . 2015,第6期

机译：Re：雄激素剥夺治疗加多西紫杉醇和雌激素与雄激素剥夺治疗单独用于高危局部前列腺癌（Getug 12）：第3期随机对照试验
4. Serum levels of sex hormones before and after androgen deprivation therapy in Japanese prostate cancer patients [C] . A. Komiya, K. Ichimatsu, A. Morii, International Congress of Andrology . 2009

机译：日本前列腺癌患者中雄激素剥夺治疗前后的性激素血清水平
5. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy [D] . TAKEI, Akinori 2019

机译：雄激素剥夺治疗的持续时间和最低20 ng / dL的睾丸激素最低值可预测接受外照射的前列腺癌患者的睾丸激素恢复至超水平
6. Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial [O] . Andrea Guttilla, Roberto Bortolus, Gianluca Giannarini, 2014

机译：高剂量强度调节放射治疗或不进行根治性前列腺切除术同时使用大剂量紫杉杉醇和长期雄激素剥夺治疗的多模式治疗高危前列腺癌的多模式治疗：一项前瞻性II期试验的结果
7. LBA18 IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS)IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS) [O] . Olivier Cussenot, Raphaele Renard Penna, Eva Comperat, 2018

机译：LBA18瞬态抗剥夺治疗（ADT）对Leuprorelin LP 11.25mg对惰性前列腺癌（PC）的组织学进展的影响 - III期试验的第III期试验（AS）对Leuprorelin的影响（ADT）的影响LP 11.25 mg关于惰性前列腺癌（PC）的组织学进展（PC） - III期试验的结果与主动监测（AS）

Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial

著录项

相似文献

相关主题

期刊订阅